Indivumed is a physician-led, global oncology company committed to advancing discoveries in cancer biology to support precision oncology. Only a multiomics approach can achieve this goal – and reliable multiomics require especially high-quality biospecimens and data. Our proprietary sample collection processes and technology help preserve the integrity of RNA, DNA, and proteins as they existed in the human body. IndivuType, our cancer database, contains vast amounts of genomics, transcriptomics, proteomics, phospho-proteomics and immuno-phenotype imaging information together with clinical and outcome data, making it a unique resource for cancer research in the post-genomics era. Coupled with cutting-edge machine learning and artificial intelligence technology, the cancer database can provide deep insights into the underlying mechanisms of a patient’s cancer, addressing important needs in translational research and molecular diagnostics to ultimately deliver personalized cancer healthcare. Through its three divisions, IndivuServ, IndivuType, and IndivuTest, Indivumed offers specialized products and services that support customers in biomarker and target discovery, drug development, clinical trials, individualized therapy and more.